Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
AssigneesAlethia Biotherapeutics Inc., National Research Council of Canada
InventorsGilles Bernard Tremblay, Mario Filion, Traian Sulea
Life of this patent
Estimating the term…
Abstract
Antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma. The invention also relates to cells expressing the humanized or hybrid antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.
Claims14
An isolated antibody or antigen binding fragment thereof, comprising a light chain variable region as set forth in SEQ ID NO.:
- 8 and a heavy chain variable region as set forth in SEQ ID NO.:
- 7, wherein the antibody or antigen binding fragment thereof binds clusterin.
A pharmaceutical composition comprising an antibody or antigen binding fragment thereof, and a pharmaceutically acceptable carrier, wherein the antibody or antigen binding fragment thereof comprises a light chain variable region as set forth in SEQ ID NO.:
- 8 and a heavy chain variable region as set forth in SEQ ID NO.:
- 7, and wherein the antibody or antigen binding fragment thereof binds clusterin.
Dependencies are inferred from the claim text.